Loading…
CO-AMILOFRUSE is a brand name for Amiloride. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Co-amilofruse is a potassium sparing diuretic which is indicated where a prompt diuresis is required. It is of particular value in conditions where potassium conservation is important: congestive cardiac failure, nephrosis, corticosteroid therapy, oestrogen therapy and for ascites associated with cirrhosis.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults One tablet, which should be taken in the morning but may be increased to two tablets. Elderly The dosage should be adjusted according to the therapeutic response. Children Not recommended for use in children. Method of administration Co-amilofruse tablets are best taken first thing in the morning, swallowed with a little milk or water.
Adverse effects have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Co-Amilofruse is generally well tolerated.
Blood and lymphatic system disorders Frequency not known:
Eosinophilia, haemoconcentration. Occasionally, thrombocytopenia may occur. In rare cases, leucopenia and, in isolated cases, agranulocytosis, aplastic anaemia or haemolytic anaemia may develop. Bone marrow depression has been reported as a rare complication and necessitates withdrawal of treatment.
Nervous system disorders Frequency not known:
Paraesthesia may occur. 3). Dizziness, fainting, loss of consciousness and headache.
Metabolism and nutrition disorders Frequency not known:
Serum calcium levels may be reduced; in very rare cases tetany has been observed. Blood cholesterol and blood triglyceride levels may increase during furosemide treatment. During long term therapy they will usually return to normal within six months.
Glucose tolerance may be impaired with furosemide. In patients with diabetes mellitus this may lead to a deterioration of metabolic control; latent diabetes mellitus may become manifest. As with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis after prolonged therapy.
The serum potassium concentration may decrease, especially at the commencement of treatment owing to the earlier onset action of furosemide. However, as treatment is continued, the serum potassium concentration may increase due to the later onset of action of amiloride, especially in patients with impaired renal function.
Co-Amilofruse should be discontinued before a glucose tolerance test. Co-Amilofruse should be used with particular caution in elderly patients or those with potential obstruction of the urinary tract or disorders rendering electrolyte balance precarious.
Urinary output must be secured. Patients with partial obstruction of urinary outflow, for example patients with prostatic hypertrophy or impairment of micturition have an increased risk of developing acute retention and require careful monitoring.
Where indicated, steps should be taken to correct hypotension or hypovolaemia before commencing therapy. Particularly careful monitoring is necessary in: ⎯ patients with hypotension. ⎯ patients who are at risk from a pronounced fall in blood pressure.
⎯ patients where latent diabetes may become manifest or the insulin requirements of diabetic patients may increase. ⎯ patients with gout. ⎯ patients with hepatic cirrhosis together with impaired renal function. g. associated with nephrotic syndrome (the effect of furosemide may be weakened and its ototoxicity potentiated).
Cautious dose titration is required. ⎯ symptomatic hypotension leading to dizziness, fainting or loss of consciousness can occur in patients treated with furosemide, particularly in the elderly, patients on other medications which can cause hypotension and patients with other medical conditions that are risks for hypotension.
Caution should be observed in patients liable to electrolyte deficiency. Regular monitoring of serum sodium, potassium, creatinine and glucose is generally recommended during therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss.
Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of Co-amilofruse. 73m2 body surface area as well as in cases where Co-Amilofruse is taken in combination with certain other drugs which may lead to an increase in potassium levels.
1. In patients with hypovolaemia or dehydration (with or without accompanying hypotension). 73 m² body surface area, anuria or renal failure with anuria not responding to furosemide, renal failure as a result of poisoning by nephrotoxic or hepatotoxic agents or renal failure associated with hepatic coma, hyperkalaemia, severe hypokalaemia, severe hyponatraemia, concomitant potassium supplements or potassium-sparing diuretics, pre-comatose states associated with cirrhosis, Addison's disease, and breast- feeding women.
Co-Amilofruse is contraindicated in children and adolescents under 18 years of age as safety in this age group has not yet been established.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Amiloride in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
g. where higher furosemide doses are administered to patients with normal renal function, acute severe electrolyte losses, although amiloride may contribute to the development or aggravation of metabolic acidosis. Warning signs of electrolyte disturbances include increased thirst, headache, hypotension, confusion, muscle cramps, tetany, muscle weakness, disorders of cardiac rhythm and gastrointestinal symptoms.
Disturbances of electrolyte balance, particularly if pronounced, must be corrected. g. in decompensated cirrhosis of the liver) may be aggravated by furosemide treatment. Pseudo-Bartter syndrome may occur in the context of misuse and/or long-term use of furosemide.
The diuretic action of furosemide may lead to or contribute to hypovolaemia and dehydration, especially in elderly patients. As with other diuretics, treatment with furosemide may lead to increases in blood creatinine and blood uric acid, hyponatremia, hypochloremia, hypokalaemia, attacks of gout, hypocalcemia, hypomagnesemia and increased blood urea.
g. in nephritic syndrome) and/or when intravenous furosemide has been given too rapidly.
Tinnitus Frequency uncommon:
Cases of deafness, sometimes irreversible have been reported after administration of furosemide.
Vascular disorders Frequency not known:
Furosemide may cause a reduction in blood pressure (hypotension) which, if pronounced may cause signs and symptoms such as impairment of concentration and reactions, light-headedness, sensations of pressure in the head, headache, dizziness, drowsiness, weakness, disorders of vision, dry mouth, orthostatic intolerance.
Vasculitis Thrombosis Hepato-biliary disorders Frequency not known:
In isolated cases, cholestasis and transaminases increases may develop.
Skin and subcutaneous tissue disorders Frequency not known:
The incidence of allergic reactions, such as skin rashes, photosensitivity, fever or shock is very low, but when these occur treatment should be withdrawn. g. pruritis, urticaria, rashes, dermatitis bullous, erythema multiforme, pemphigoid, dermatitis exfoliative, purpura, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, AGEP (acute generalized exanthematous pustulosis) and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms), lichenoid reactions.
Psychiatric disorders Frequency not known:
Rare complications may include minor psychiatric disturbances.
Renal and urinary disorders Frequency not known:
Increased urine volume may provoke or aggravate complaints in patients with an obstruction of urinary outflow. Urine sodium increased, urine chloride increased, urine retention with possible secondary complications may occur. for example, in patients with bladder-emptying disorders, prostatic hyperplasia or narrowing of the urethra.
Nephrocalcinosis / Nephrolithiasis has been reported in premature infants. Tubulointerstitial nephritis Renal failure Reproductive system and breast disorders Frequency not known: If furosemide is administered to premature infants during the first weeks of life, it may increase the risk of persistence of patent ductus arteriosus.
g. with shock) occur rarely. Exacerbation or activation of systemic lupus erythematosus.
Gastrointestinal disorders Frequency not known:
Side-effects of a minor nature such as nausea, malaise or gastric upset (vomiting or diarrhoea) and constipation may occur but are not usually severe enough to necessitate withdrawal of treatment. Pancreatitis acute. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued […]
In patients who are at high risk for radiocontrast nephropathy, furosemide is not recommended to be used for diuresis as part of the preventative measures against radiocontrast-induced nephropathy. 1%; mean age 80 years, range 67-90 years).
Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings. No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed.
Nevertheless, caution should be exercised and the risks and benefits of this combination or co-treatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with risperidone.
3). The possibility exists of exacerbation or activation of systemic lupus erythematosus. Co-amilofruse Tablets contain Sunset yellow aluminium lake (E110), which may cause allergic reactions.